International Circumpolar Surveillance (ICS) Summary Report, year 2010 data by Zulz, Tammy et al.
 INTERNATIONAL CIRCUMPOLAR SURVEILLANCE (ICS) SUMMARY REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YEAR 2010 DATA 
TABLE OF CONTENTS 
 
           Page 
 
Summary                 1 
 
Introduction                 2  
 
Goals                  2 
 
Methods                 3  
 
Results 
 Streptococcus pneumoniae              8 
 Haemophilus influenzae            16 
 Neisseria meningitidis            20 
 Group A Streptococcus            22 
 Group B Streptococcus            25 
 
Conclusions               28 
 
Acknowledgements              28 
 
Source               28 
 
References               29 
 
Participants               30 
 
 
 1 
SUMMARY 
 
International Circumpolar Surveillance (ICS) is a population-based surveillance system for invasive bacterial 
diseases established in the U.S. Arctic, Northern Canada, Greenland, Iceland, Norway, Finland, and Northern 
Sweden.  Data collection began in 1999 and includes information on disease caused by Streptococcus 
pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and groups A and B Streptococcus (GAS, GBS).  
This report reviews the data collected for the year 2010. 
 
Data on invasive disease with the organism S. pneumoniae are collected from all participating countries.  A total 
of 1,874 cases of invasive pneumococcal disease were identified in 2010.  Overall, rates of invasive S. 
pneumoniae were highest in individuals less than 2 years of age or in persons 65 years and older.  Case fatality 
ratios ranged from 7-14%.  Race and ethnicity data are collected only in N. Canada and the U.S. Arctic; rates of 
invasive pneumococcal disease in Northern Canadian Aboriginals and U.S. Arctic Native populations were 36 
and 31 cases per 100,000 population, respectively, which represents a slight decrease in disease from 2009 in 
these populations.  Pneumonia, bacteremia and meningitis were the most common clinical presentations; 
cigarette smoking alcohol abuse, and chronic lung disease were the most common risk factors.  The most 
common S. pneumoniae serotype in Iceland was 14; in Greenland, N. Canada and the U.S. Arctic the most 
common serotype was 7F. 
 
Data on invasive disease due to H. influenzae, N. meningitidis, and groups A and B Streptococcus are currently 
collected in Greenland, Northern Canada, Northern Sweden and the U.S. Arctic; Norway also contributes data 
on cases of N. meningitidis and H. influenzae.  A total of 137 H. influenzae cases, 42 N. meningitidis cases, 63 
GAS cases, and 68 GBS cases were reported in 2010.  In general, the highest rates of disease for all organisms 
occurred in N. Canada Aboriginal or Alaska Native persons less than two years of age and persons 65 and older. 
 
Surveillance Organisms Reported by Country, ICS 2010 Data 
 
Country 
S. pneumoniae 
n (rate*) 
H. influenzae 
n (rate*) 
N. meningitidis 
n (rate*) 
GAS 
n (rate*) 
GBS 
n (rate*) 
Finland 850 (15.8) N/A N/A N/A N/A 
Greenland 10 (17.7) 0 (0) 0 (0) 0 (0) 0 (0) 
Iceland 37 (11.6) N/A N/A N/A N/A 
N. Canada 30 (19.8) 17 (11.2) 1 (0.7) 12 (7.9) 3 (2) 
N. Sweden 84 (16.5)† 2 (0.8)‡ 1 (0.4)‡ 9 (3.6)‡ 12 (4.8)‡ 
Norway 748 (15.4) 89 (1.8) 39 (0.8) N/A N/A 
U.S. Arctic 115 (16.2) 29 (4.1) 1 (0.1) 42 (5.9) 53 (7.5) 
Total 1,874 (15.6) 137 (2.3) 42 (0.7) 63 (5.4) 68 (5.4) 
*Cases per 100,000 
† Norbotten & Vasterbotten 
‡Norbotten  
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INTRODUCTION 
 
In January, 1999, the United States and Canada began international cooperative population-based surveillance 
for invasive S. pneumoniae by all laboratories serving residents of the North American Arctic.  In January, 
2000, this surveillance system expanded to include invasive diseases with the following organisms:  H. 
influenzae (all types), N. meningitidis, GAS, and GBS.  These pathogens were selected for ICS because rates of 
these diseases are elevated in indigenous peoples of the north, strains demonstrate resistance to commonly used 
antibiotics, they are routinely cultured in clinical laboratories, and clinically important serotypes of S. 
pneumoniae, H. influenzae, and N. meningitidis are vaccine preventable in infants and adults. 
 
Denmark’s autonomous region of Greenland joined ICS in 2000; Iceland, Norway (including Svalbard), and 
Finland joined in 2001; the Northern Sweden regions of Norbotten and Vasterbotten joined in 2003 and 2006, 
respectively.   
 
GOALS 
 
The goal of ICS is to establish an integrated network of hospital and public health facilities throughout the 
Arctic countries to monitor infectious diseases of concern.  Linking public health facilities within Arctic nations 
will allow for the collection and sharing of uniform laboratory and epidemiological data that will describe the 
prevalence of infectious diseases in Arctic populations and assist in the formulation of prevention and control 
strategies. 
 
The project, initiated in 1998, focused on establishing an ICS system for diseases caused by S. pneumoniae.  
This bacterium causes pneumonia, meningitis, and bacteremia in both the very young and the elderly.  Once 
easily treated with antibiotics, this bacterium has become resistant to commonly used antibiotics.  This is of 
great concern to the public health community and is increasingly a target for surveillance by many countries 
worldwide.  A polysaccharide vaccine is available for use in persons two years of age and older.  A conjugate 
vaccine for infants has been developed and is licensed for use in the U.S., Canada, and the European Union.  
The fact that diseases caused by S. pneumoniae were already being monitored by many public health authorities 
within the Arctic states made establishing a circumpolar surveillance system for this infection feasible.  In 
addition, due to the availability of polysaccharide and conjugate vaccines, much of the morbidity and mortality 
caused by S. pneumoniae is currently preventable. 
 
ICS objectives include: 
 
• Identify key public health contacts within Arctic countries.  These persons should be familiar with infectious 
disease surveillance systems in place (particularly surveillance systems for diseases caused by S. 
pneumoniae) in the member country.  Through correspondence and working group meetings, the scope and 
gaps of the surveillance systems are determined. 
 
• Determine the comparability of laboratory and data collection methods, and negotiate standard protocols 
and quality control programs. 
 
• Share and report data in agreed upon formats. 
 
• Form a working group of key laboratory and public health contacts to coordinate pneumococcal surveillance 
within their respective jurisdictions.  This group meets on a regular basis to review problems, progress, 
compliance, report generation, and future plans. 
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• Form a steering committee of national Arctic health experts to coordinate new objectives and initiatives 
within ICS. 
 
This program forms a framework through which surveillance of other infectious diseases as well as prevention 
and control programs can be added.  Other infectious diseases of circumpolar community concern include:  
other invasive bacterial diseases (caused by H. influenzae, N. meningitidis, GAS, and GBS), tuberculosis, HIV, 
hepatitis, foodborne diseases (botulism, brucellosis), waterborne diseases, respiratory diseases of children such 
as those caused by respiratory syncytial virus, chronic conditions related to infectious agents (hepatitis B virus 
and liver cancer, human papilloma virus and cervical cancer, H. pylori and stomach cancer) and climate 
sensitive diseases.  In addition, the surveillance model developed by this program for infectious disease may be 
adapted to monitor other non-infectious human health priorities of community concern. 
 
METHODS 
 
ICS is coordinated by personnel at the Arctic Investigations Program (AIP), Centers for Disease Control and 
Prevention, in Anchorage, Alaska. 
 
A case of invasive S. pneumoniae, H. influenzae, N. meningitidis, GAS or GBS is defined by the isolation of the 
bacteria from a normally sterile site, (including blood, cerebrospinal fluid, pleural fluid, peritoneal fluid or joint 
fluid) that has been taken from a resident of the surveillance area. 
 
In the U.S. Arctic and Northern Canada, laboratory, demographic and clinical data are collected continually by 
ICS, while in Greenland, Iceland, Northern Sweden, Norway, and Finland, summary data are submitted to ICS 
in aggregate at the end of the year. 
 
Surveillance System Description by Country/Region 
 
The following table outlines the organisms reported and data provided by each country or region. 
 
Data Provided by Country/Region, ICS 2010 
Country S
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Finland X      X     X 
Greenland X X X X X X X   X  X 
Iceland X     X X   X  X 
N. Canada X X X X X X X X X X X X 
N. Sweden X X X X X  X     X 
Norway X X X    X   X X  
U.S. Arctic X X X X X X X X X X X X 
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Finland 
 
• 23 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Finland. 
o All invasive isolates of S. pneumoniae submitted to the National Public Health Institute (KTL) 
laboratory in Oulu. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates was performed by agar dilution method at 
district hospital laboratories as well as the KTL laboratory. 
 
• Population estimates for 2010 were obtained from the website http://www.stat.fi 
 
Greenland 
 
• 15 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Greenland. 
o All invasive isolates of S. pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS submitted to 
reference laboratories in Nuuk and Copenhagen. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates was performed by agar dilution at the central 
laboratory at Queen Ingrid’s Hospital in Nuuk. 
 
• Serotyping was performed at the Statens Serum Institute in Copenhagen, Denmark, by the Quellung 
method. 
 
• Clinical and demographic data for every case of invasive S. pneumoniae, H. influenzae, N. meningitidis, 
GAS, and GBS was collected by public health authorities at the end of the year and entered onto a 
standardized collection tool, the Bacterial Diseases Surveillance Form (BDSF), which is also used in 
Iceland, Northern Canada, and the U.S. Arctic. 
 
• Population estimates for 2010 were obtained from the website http://www.stat.gl 
 
Iceland 
 
• 10 district hospital laboratories and one regional laboratory participate in ICS. 
o Provide diagnostic microbiology services for all residents of Iceland. 
o All invasive isolates of S. pneumoniae submitted to the reference hospital in Reykjavik. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates is performed by disc diffusion method at the 
Landspitali University Hospital (LUH) in Reykjavik and the laboratory at the regional hospital in Akureyri.  
All oxacillin resistant isolates are then analyzed by E test. 
 
• Serotyping is performed at the LUH by coagglutination using antisera from Statens Serum Institute. 
 
• Clinical and demographic data for every case of invasive S. pneumoniae was collected by public health 
authorities at the end of the year and entered onto the same collection form (BDSF) used in Greenland, 
Northern Canada, and the U.S. Arctic. 
 
• Population estimates for 2010 were obtained from th
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Northern Canada 
 
• 14 Canadian laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of the Yukon Territory, Northwest Territories, 
Nunavut, Northern Quebec, and Northern Labrador. 
o Submit all invasive isolates of S. pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS to one of 
two reference laboratories in Canada. 
o S. pneumoniae, H. influenzae, GAS, and GBS isolates are serotyped by the Quellung method using 
Statens Serum Institute antisera. 
 
• Antimicrobial susceptibility of S. pneumoniae, GAS, and GBS isolates was tested by micro-broth dilution 
(according to NCCLS recommendations). 
 
• Communicable disease consultants located within one of the five regions of Northern Canada provided 
clinical and demographic information on the same collection form (BDSF) used in Greenland, Iceland, and 
the U.S. Arctic. 
 
• Population estimates for 2010 were obtained from the website http://www.statcan.ca 
 
Northern Sweden 
 
• 1 district laboratory participates in ICS. 
o Provides diagnostic microbiology services for all residents of Norrbotten and Vasterbotten counties. 
o The main reference laboratory is at the Swedish Institute for Infectious Disease Control in Stockholm. 
o Isolates are serotyped by the Quellung method. 
• Antimicrobial susceptibility testing was by disc diffusion at the University Hospital in Umea and Sunderby 
Hospital in Lulea. 
 
• Population estimates for 2010 were obtained from the website http://www.scb.se/default____2154.asp 
 
Norway 
 
• 33 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Norway. 
o All invasive isolates of S. pneumoniae submitted to one of two reference laboratories in Oslo or Tromsö. 
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates is performed using the disc diffusion method 
at district hospital laboratories, the reference laboratory in Tromsö or the main national laboratory in Oslo. 
 
• Serotyping is performed at the Statens Serum Institute in Denmark by the Quellung method. 
 
• Population estimates for 2010 were obtained from the website http://www.ssb.no 
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U.S. Arctic 
 
• 23 laboratories providing diagnostic services to residents of Alaska submitted to AIP isolates of S. 
pneumoniae, H. influenzae, N. meningitidis, GAS, and GBS cultured in blood, cerebrospinal fluid, or from 
other sterile sites. 
o S. pneumoniae and H. influenzae isolates are serotyped by the Quellung method using Statens Serum 
Institute antisera. 
o Serogroup testing of N. meningitidis was done using real-time PCR to detect the ctaA gene (capsule 
transport), as well as the genes required for serogroup-specfic capsule biosynthesis.   
 
• Antimicrobial susceptibility testing of S. pneumoniae isolates is performed at AIP by micro-broth dilution 
(according to NCCLS recommendations). 
 
• Clinical and demographic information on each case-patient is recorded by AIP research nurses onto the 
same collection form (BDSF) used in Greenland, Iceland, and Northern Canada. 
 
• Population estimates for 2010 were obtained from the website http://www.labor.state.ak.us 
 
Quality Control 
 
Streptococcus pneumoniae:  Clinical laboratories in the U.S. Arctic and N. Canada forward isolates from 
patients with invasive pneumococcal disease to reference laboratories in their respective country.  To ensure 
inter-laboratory comparability of S. pneumoniae serotyping and antimicrobial susceptibility testing between two 
reference laboratories in Canada (Alberta and Quebec) and one in the U.S. (Alaska), the ICS S. pneumoniae 
inter-laboratory quality control (QC) program was established in 1999.  Statens Serum Institute, Copenhagen, 
Denmark, joined the program in 2004. Each reference laboratory is responsible for exporting one QC panel of 
seven S. pneumoniae isolates every other year to each of the other laboratories [1]. 
 
Neisseria meningitidis/Haemophilus influenzae:  An interlaboratory quality control program for Neisseria 
meningitidis and Haemophilus influenzae was established in 2005.  Participating laboratories include the 
National Microbiology Laboratory, Winnipeg, Manitoba, Canada; Arctic Investigations Program, Anchorage, 
Alaska, USA; Laboratoire Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada; National 
Centre for Streptococcus, Edmonton, Alberta, Canada; and Statens Serum Institut, Copenhagen, Denmark.  
Strain panels are distributed twice a year from the National Microbiology Laboratory or Arctic Investigations 
Program [2]. 
 
 
  
 7 
Participating Countries, ICS 2010 
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RESULTS 
 
Streptococcus pneumoniae 
 
Case Demographics 
 
A total of 1,874 cases of invasive disease caused by S. pneumoniae were reported to ICS during 2010 by 
Finland, Greenland, Iceland, N. Canada, N. Sweden, Norway, and the U.S. Arctic.  The highest rates of disease 
(17.7 per 100,000) occurred in N. Canada and the lowest in Iceland (11.6 per 100,000) with an overall rate for 
the ICS circumpolar region of 15.6 per 100,000; 54% of all cases occurred in males.  The median age of cases 
overall was 62.3 years with the lowest median age in N. Canada (54 years) and the highest in Norway (65.6 
years).  Case fatality ratios ranged from 6.7% in N. Canada to 13.5% in Iceland; the overall case fatality ratio 
was 11.4%. 
 
Streptococcus pneumoniae Case Demographics, ICS 2010 Data 
Country Population 
# 
Cases Rate* 
Sex  
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR†) 
Finland 5,375,276 850 15.8 470 (55) 59.5 (0-97.4) ‡ 
Greenland 56,452 10 17.7 7 (70) 57.8 (1.2-82.6) 1 (11.1%)b 
Iceland 317,630 37 11.6 21 (57) 61.4 (0.6-95.9) 5 (13.5%) 
N. Canada 151,578 30 19.8 18 (60) 54 (0.8-89.8) 2 (6.7%) 
N. Sweden 507,826a 84 16.5 39 (46) 65.2 (0.1-95.6) ‡ 
Norway 4,858,199 748 15.4 385 (51) 65.6 (0.1-101.2) 44 (11.8%)b 
U.S. Arctic 710,231 115 16.2 69 (60) 55.2 (0.3-95.4) 12 (10.6%)b 
Total 11,977,192 1,874 15.6 1,009 (54) 62.3 (0-101.2) 64 (11.4%) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Case outcomes not reported from Finland, N. Sweden 
a Population for Norbotten and Vasterbotten 
b Case outcomes unknown in 1 case from Greenland, 374 cases from Norway, 2 cases from U.S. Arctic 
 
Streptococcus pneumoniae by Age Category, ICS 2010 Data 
Age  Finland Greenland Iceland N. Canada N. Sweden Norway U.S. Arctic 
<2 yrs 
Pop 121,919 1,695 9,778 5,651 9,986 123,626 21,834 
N (%)* 71 (8) 1 (10) 4 (11) 2 (7) 1 (1) 25 (3) 10 (9) 
Rate† 58.2 59 40.9 35.4 10 20.2 45.8 
2-19 
yrs 
Pop 1,097,842 15,749 80,515 44,672 101,420 1,116,131 186,006 
N (%)* 63 (7) 0 (0) 2 (5) 1 (3) 2 (2) 22 (3) 14 (12) 
Rate† 5.7 0 2.5 2.2 2 2 7.5 
20-64 
yrs 
Pop 3,214,474 35,161 189,268 92,854 293,628 2,895,769 447,453 
N (%)* 405 (48) 6 (60) 15 (41) 19 (63) 35 (42) 309 (41) 61 (54) 
Rate† 12.6 17.1 7.9 20.5 11.9 10.7 13.6 
65+ 
yrs 
Pop 941,041 3,847 38,069 8,401 102,792 722,673 54,938 
N (%)* 311 (37) 3 (30) 16 (43) 8 (27) 46 (55) 392 (52) 30 (26) 
Rate† 33.1 78 42 95.2 44.8 54.2 54.6 
All 
ages 
Pop 5,375,276 56,452 317,630 151,578 507,826 4,858,199 710,231 
N 850 10 37 30 84 748 115 
Rate† 15.8 17.7 11.6 19.8 16.5 15.4 16.2 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
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When stratified by age, the highest rates of disease in all countries occurred either in those cases less than two 
years of age or in cases 65+ years of age. 
 
Seasonality 
 
S. pneumoniae was diagnosed throughout the year in 2010 in each country.  For all countries except Greenland, 
higher proportions of disease were seen in the first and second quarters of the year with declines during the third 
quarter and rising again during the fourth quarter.  In Greenland, the highest proportion of cases was seen in the 
third quarter and the lowest in the second quarter of the year, however, due to the small number of cases, 
seasonality cannot be described. 
 
Race 
 
Race and ethnicity data were collected in N. Canada and the U.S. Arctic.  Rates of invasive pneumococcal 
disease were higher in Aboriginal and Native populations than in non-Aboriginal and non-Native populations.  
The highest rates of disease occurred in children less than 2 years of age and adults 65+ in both countries.   
 
Streptococcus pneumoniae by Race and Age Categories, ICS 2010 Data 
Age 
(yrs) 
 N. Canada* U.S. Arctic 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,834 1,817 6,191 15,643 Cases (rate‡) 2 (52.2) 0 (0) 8 (129.2) 2 (12.8) 
2-19 Population 34,594 10,078 49,754 136.252 Cases (rate‡) 1 (2.9) 0 (0) 10 (20.1) 4 (2.9) 
20-64 Population 44,126 48,728 75,228 372,225 Cases (rate‡) 17 (38.5) 1 (2.1)  23 (30.6) 38 (10.2) 
65+ Population 3,610 4,791 8,551 46,387 Cases (rate‡) 7 (193.9) 1 (20.9) 10 (117) 20 (43.1) 
All 
Ages 
Population 86,164 65,414 139,724 570,507 
Cases (rate‡) 27 (31.3) 2 (3.1) 51 (36.5) 64 (11.2) 
*Race unknown in 1 case 20-64 years 
‡Number of cases per 100,000 per year 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the pneumococcal infection was recorded as the primary clinical 
presentation. The most common clinical presentations associated with S. pneumoniae were pneumonia, 
bacteremia, and meningitis.  In Greenland, N. Canada, and the U.S. Arctic the clinical presentation reported 
most often was pneumonia (80%, 60%, and 66%, respectively), in Norway it was bacteremia (53%).  
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Clinical Presentation of Reported Streptococcus pneumoniae Cases, ICS 2010 Data 
 Finland 
n (%) 
Greenland 
n (%) 
Iceland 
n (%) 
N Canada 
n (%) 
N Sweden 
n (%) 
Norway 
n (%) 
US Arctic 
n (%) 
Pneumonia* 0 (0) 8 (80) 0 (0) 18 (60) 0 (0) 254 (34) 76 (66) 
Bacteremia 801 (94) 1 (10) 34 (92) 6 (20) 80 (95) 393 (53) 17 (15) 
Meningitis 49 (6) 0 (0) 3 (8) 3 (10) 4 (5) 47 (6) 7 (6) 
Empyema 0 (0) 0 (0) 0 (0) 1 (3) 0 (0) 0 (0) 11 (10) 
Septic arthritis 0 (0) 1 (10) 0 (0) 1 (3) 0 (0) 0 (0) 1 (1) 
Endocarditis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
Cellulitis 0 (0) 0 (0) 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 
Other 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 49 (7) 2 (2) 
Unknown 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (<1) 0 (0) 
Total Cases 850 10 37 30 84 748 115 
*with bacteremia 
 
Risk Factors 
 
Greenland, N. Canada and the U.S. Arctic reported medical conditions or risk factors associated with S. 
pneumoniae.  In adults 18 years and older, cigarette smoking and alcohol abuse were the most common 
associated conditions in Greenland and N. Canada; in the U.S. Arctic, the most common associated conditions 
were cigarette smoking and chronic lung disease. 
 
Streptococcus pneumoniae Risk Factor/Medical Conditions in Adults*, ICS 2010 Data† 
 Greenland 
n (%) 
N. Canada 
n (%) 
U.S. Arctic 
n (%) 
Cigarette Smoking 4 (44) 7 (26) 44 (48) 
Alcohol Abuse 2 (22) 8 (30) 31 (34) 
Chronic Lung Disease and/or Asthma 1 (11) 3 (11) 34 (37) 
Immunosuppressive Therapy 1 (11) 2 (7) 7 (8) 
Diabetes 0 (0) 6 (22) 23 (25) 
Injection Drug Use 0 (0) 0 (0) 1 (1) 
Asplenia 0 (0) 0 (0) 2 (2) 
Total Adult* Cases 9 27 92 
*≥ 18 years 
†Multiple risk factors may be reported per case 
 
Vaccination Policy 
 
In Finland, Iceland, N. Canada, Norway, and the U.S. Arctic, 23-valent pneumococcal polysaccharide vaccine 
(PS23) is recommended for persons over 60 years (Iceland) or over 65 years of age (Finland, N. Canada, 
Norway, U.S. Arctic), and to persons greater than two years of age (Finland, Iceland, Norway, U.S. Arctic) or 
greater than five years of age (N. Canada) with specific medical problems.  The vaccine is only recommended 
for certain risk groups in N. Sweden.  Three pneumococcal conjugate vaccines (PCV), PCV7, PCV10, and 
PCV13, for use in children under the age of 2 years have been used in ICS regions since 2001.  Vaccines used 
and years introduced are presented in the table below. 
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Pneumococcal Vaccines Introduced, ICS 2010 Data 
 Finland Greenland Iceland N Canada N Sweden Norway US Arctic 
PCV7    2002-2006* 2007 2007 2001 
PCV10 2010   2009-2010*    
PCV13  2010  2010* 2010  2010 
PS23 † 1996 † 1988 1994 † 1983 
*PCV7 – N Quebec and Nunavut (2002), Newfoundland and Yukon (2005), Northwest Territory (2006); PCV10 – Nunavut (2010); 
PCV13 – N Quebec did not introduce PCV13 in 2010 
†PS23 used but year of introduction unknown 
 
Vaccination Status 
 
Fifty-six percent of S. pneumoniae cases in children less than 2 years of age with known vaccination status were 
vaccinated with a PCV in Norway; in N. Canada and the U.S. Arctic, 100% of children with known vaccine 
status were vaccinated.  Only 3% of cases eligible for PS23 in Norway were vaccinated indicating much less 
frequent use of this vaccine than in N. Canada and the U.S. Arctic.  Vaccine coverage data were not reported 
from Finland and Iceland.   
 
Streptococcus pneumoniae Case Vaccination Status for Pneumococcal Vaccine, ICS 2010 Data 
 N. 
Canada Norway 
U.S. 
Arctic 
Total cases eligible for PCV7 vaccine* 2 25 10 
Vaccine status known in cases eligible for PCV7 1 18 9 
Cases eligible for PCV7 vaccinated (%)† 1 (100%) 10 (56%) 9 (100%) 
Total cases eligible for PS23 vaccine‡ 8 392 30 
Vaccine status known in cases eligible for PS23 7 74 17 
Cases eligible for PS23 vaccinated (%)† 5 (71%) 2 (3%) 14 (82%) 
*Children less than 2 years of age 
†Percent of vaccine status known cases 
‡Adults 65 years and older 
 
Serotypes 
 
The S. pneumoniae serotypes reported by ICS regions in 2010 are listed in the following table; yellow 
highlights the most common serotypes in each country.  Serotypes included in the conjugate vaccines were the 
most prevalent in Iceland; PCV was not included in their universal vaccine program in 2010.    
 
 Streptococcus pneumoniae Serotypes by Country, ICS 2010 Data 
Serotype 
Greenland† 
n (%) 
Iceland 
n (%) 
N. Canada† 
(%) 
N. Sweden*† 
n (%) 
U.S. Arctic† 
n (%) 
1‡ 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 
3‡ 1 (10) 4 (11) 3 (11) 4 (10) 11 (11) 
4‡ 3 (30) 2 (5) 0 (0) 1 (2) 1 (1) 
6 0 (0) 0 (0) 0 (0) 4 (10) 0 (0) 
6A‡ 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 
6B‡ 1 (10) 2 (5) 0 (0) 0 (0) 0 (0) 
6C 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 
7 0 (0) 0 (0) 0 (0) 3 (7) 0 (0) 
7F‡ 4 (40) 4 (11) 4 (15) 0 (0) 20 (20) 
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Serotype 
Greenland† 
n (%) 
Iceland 
n (%) 
N. Canada† 
(%) 
N. Sweden*† 
n (%) 
U.S. Arctic† 
n (%) 
8 0 (0) 0 (0) 4 (15) 2 (5) 4 (4) 
9N 0 (0) 1 (3) 1 (4) 0 (0) 6 (6) 
9V‡ 0 (0) 2 (5) 0 (0) 0 (0) 0 (0) 
10 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 
10A 0 (0) 0 (0) 3 (11) 0 (0) 2 (2) 
11 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 
11A 0 (0) 0 (0) 0 (0) 0 (0) 4 (4) 
11B 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 
12 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
12F 0 (0) 0 (0) 1 (4) 0 (0) 4 (4) 
14‡ 0 (0) 5 (14) 0 (0) 1 (2) 0 (0) 
15 0 (0) 0 (0) 0 (0) 2 (5) 0 (0) 
15A 0 (0) 0 (0) 1 (4) 0 (0) 2 (2) 
15B 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 
15C 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 
16F 0 (0) 0 (0) 0 (0) 0 (0) 6 (6) 
18 0 (0) 0 (0) 0 (0) 7 (17) 0 (0) 
18C‡ 0 (0) 2 (5) 1 (4) 0 (0) 0 (0) 
19 0 (0) 0 (0) 0 (0) 4 (10) 0 (0) 
19A‡ 0 (0) 3 (8) 2 (7) 0 (0) 18 (18) 
19C 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 
19F‡ 0 (0) 3 (8) 1 (4) 0 (0) 1 (1) 
20 0 (0) 0 (0) 0 (0) 0 (0) 4 (4) 
22 0 (0) 1 (3) 0 (0) 6 (14) 0 (0) 
22A 0 (0) 0 (0) 1 (4) 0 (0) 0 (0) 
22F 0 (0) 0 (0) 4 (15) 0 (0) 2 (2) 
23 0 (0) 0 (0) 0 (0) 4 (10) 0 (0) 
23A 0 (0) 0 (0) 0 (0) 0 (0) 6 (6) 
23B 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
23F‡ 0 (0) 2 (5) 0 (0) 0 (0) 0 (0) 
29 0 (0) 1 (3) 0 (0) 0 (0) 1 (1) 
31 0 (0) 0 (0) 0 (0) 1 (2) 1 (1) 
33 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 
33F 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
35 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 
35B 0 (0) 0 (0) 1 (4) 0 (0) 0 (0) 
35F 1 (10) 0 (0) 0 (0) 0 (0) 1 (1) 
38 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
# Isolates 
Serotyped 10 37 27 42 102 
*Serogroup level data from Vasterbotten 
†PCV included in universal vaccine program 
‡Serotype included in PCV 
 
 
 
 
 13 
Cases and Deaths with Vaccine Serotypes 
 
For the countries reporting serotype data, more than 77% of S. pneumoniae cases in persons ≥ 2 years of age 
had a serotype that was included in the 23-valent polysaccharide vaccine.  Fifty percent to 100% of Strep 
pneumoniae cases in children < 2 years of age had a serotype contained in the PCV13 vaccine.  With the 
introduction of PCV13 in Greenland, N. Canada and the U.S. Arctic, the number of cases caused by vaccine 
serotypes should decline over time.  The proportion of deaths with serotypes in the 23-valent polysaccharide 
vaccine related to S. pneumoniae ranged from 50% to 100%. 
 
Proportion of Cases/Deaths with Invasive Pneumococcal Disease Vaccine Serotypes, ICS 2010 Data 
 Greenland 
n/Denom* 
(%) 
Iceland 
n/Denom* 
(%) 
N. Canada 
n/Denom* 
(%) 
U.S. Arctic 
n/Denom* 
(%) 
Cases ≥ 2 years old with serotype in the 
23-valent pneumococcal polysaccharide 
vaccine 
9/9 
(100) 
28/33 
(85) 
22/25 
(88) 
71/92 
(77) 
Cases < 2 years old with serotype in the 
13-valent pneumococcal conjugate 
vaccine 
1/1 
(100) 
3/4 
(75) 
1/2 
(50) 
8/10 
(80) 
Deaths (all ages) for which the serotype 
was contained in the 23-valent 
pneumococcal vaccine 
 
1 (100‡) 
 
5 (100‡) 
 
1 (50‡) 
 
8 (67‡) 
*Number of isolates serotyped by country by age group 
‡Percentage of total death 
 
Outcome 
 
A total of 64 deaths associated with S. pneumoniae were reported to ICS in 2010.  Overall, the highest case 
fatality ratio (CFR) occurred in persons 65+ years of age (19%).  Finland and N. Sweden did not report outcome 
data. 
 
Streptococcus pneumoniae Age-Specific Case-Fatality Ratios (CFR), ICS 2010 Data 
  <2 years 2-19 years 20-64 years 65+ years All Ages 
Greenland Deaths/Cases* (CFR) 
0/1 
(0%) 
0/0 
(0%) 
0/5† 
(0%) 
1/3 
(33%) 
1/9 
(11%) 
Iceland Deaths/Cases* (CFR) 
0/4 
(0%) 
0/2 
(0%) 
1/15 
(7%) 
4/16 
(25%) 
5/37 
(13.5%) 
N. Canada Deaths/Cases* (CFR) 
0/2 
(0%) 
0/1 
(0%) 
1/19† 
(5%) 
1/8 
(13%) 
2/30 
(6.7%) 
Norway Deaths/Cases* (CFR) 
1/16† 
(6%) 
0/15† 
(0%) 
9/154† 
(6%) 
34/189† 
(18%) 
44/374 
(11.8%) 
U.S. Arctic Deaths/Cases* (CFR) 
0/10 
(0%) 
1/14 
(7%) 
4/59† 
(7%) 
7/30 
(23%) 
12/113 
(10.6%) 
Total Deaths/Cases* (CFR) 
1/33 
(3%) 
1/32 
(3%) 
15/252 
(6%) 
47/246 
(19%) 
64/563 
(11.4%) 
*Cases with known outcome.   
†Outcome unknown in (9) Norway cases < 2 years; (7) Norway cases 2-19 years; (1) Greenland, (1) N. Canada, (155) Norway, and 2 
US Arctic cases 20-64 years; (203) Norway cases 65+ years 
 
Antimicrobial Susceptibility 
 
 14 
In 2010, antimicrobial susceptibility results were reported to ICS from Finland, Greenland, Iceland, N. Canada, 
N. Sweden and the U.S. Arctic.  The following table outlines for each country the antibiotics tested, the number 
of isolates reported tested for each antibiotic and the proportion (NS%) of isolates tested that showed any level 
of non-susceptibility. 
 
Streptococcus pneumoniae Antibiotic Susceptibility Testing, ICS 2010 Data 
 Antibiotic 
Finland 
n (NS%) 
Greenland 
n (NS%) 
Iceland 
n (NS%) 
N. Canada 
n (NS%) 
N. Sweden 
n (NS%) 
U.S. Arctic 
n (NS%) 
Ceftriaxone - - 37 (0%) 16 (0%) 5 (0%) 101 (5%) 
Chloramphenicol - - 37 (0%) 21 (0%) - 101 (0%) 
Clindamycin - - - 21 (0%) 42 (0%) 101 (8%) 
Erythromycin - 10 (0%) 37 (11%) 21 (5%) 84 (2%) 101 (14%) 
Levofloxacin - - - 22 (0%) - 101 (0%) 
Penicillin 850 (3%) 10 (0%) 37 (5%) 22 (0%) 83 (0%) 101 (21%) 
Rifampin - - - - - 101 (21%) 
TMP Sulfa* - - 37 (11%) 23 (0%) 44 (18%) 101 (16%) 
Vancomycin - - - 23 (0%) - 101 (0%) 
*Trimethoprimsulfamethoxizole 
 
Of the antibiotics tested, the largest numbers of isolates were resistant to penicillin, TMP-Sulfa and 
erythromycin.  Results by country for each of these antibiotics are shown in the tables below.  In the U.S. 
Arctic, 36 isolates comprised of 8 serotypes (3, 6A, 6C, 14, 15A, 19A, 19F, 33F) showed multi-drug resistance.  
The largest proportion (n = 23, 64%) of the multi-drug resistant isolates was serotype 19A and 21% of isolates 
with this serotype were resistant to more than three antibiotics.  In N. Canada, one of two serotype 15A isolates 
was resistant to two antibiotics.  In Iceland, none of the isolates tested were resistant to more than one antibiotic.  
Finland and N. Sweden did not report serotypes. 
 
Streptococcus pneumoniae Penicillin Susceptibility Results, ICS 2010 Data 
 # Tested I* (%) I* Serotypes (n) R* (%) R* Serotypes (n) 
Finland 850 3 (<1%) † 19 (2%) † 
Greenland 10  0 (0%)  0 (0%)  
Iceland 37 1 (3%) 19F (1) 1 (3%) 19F (1) 
N. Canada 22 0 (0%)  0 (0%)  
N. Sweden 83 0 (0%)  0 (0%)  
U.S. Arctic 101 16 (16%) 19A (8), 23A (6), 15A (1), 29 (1) 5 (5%) 19A (5) 
*I=Intermediate resistance, R=Fully resistant 
†Serotypes not reported 
 
Streptococcus pneumoniae TMP-Sulfa Susceptibility Results, ICS 2010 Data 
 # Tested I* (%) I* Serotypes (n) R* (%) R* Serotypes (n) 
Iceland 37 0 (0%)  4 (11%) 19F (2), 23F (1), 33 (1) 
N. Canada 23 0 (0%)  0 (0%)  
N. Sweden† 44 4 (9%) 7 (1), 18 (1), 23 (1), 31 (1) 4 (9%) 6 (2), 3 (1), 18 (1) 
U.S. Arctic 101 3 (3%) 19A (1), 19F (1), 29 (1) 13 (13%) 19A (13) 
*I=Intermediate resistance, R=Fully resistant 
†N. Sweden reported serogroups only 
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Streptococcus pneumoniae Erythromycin Susceptibility Results, ICS 2010 Data 
 # Tested I* (%) I* Serotypes R* (%) R* Serotypes (n) 
Greenland 10 0 (0%)  0 (0%)  
Iceland 37 0 (0%)  4 (11%) 14 (2), 19F (2) 
N. Canada 21 0 (0%)  0 (0%)  
N. Sweden† 84 0 (0%)  2 (2%) 8 (1), 19 (1) 
U.S. Arctic 101 0 (0%)  14 (14%) 19A (8), 23A (2), 7F (1), 9N (1), 10A (1), 15A (1) 
*I=Intermediate resistance, R=Fully resistant 
†N. Sweden reported serogroups only 
 
Quality Control 
 
In 2010, two QC panels of seven S. pneumoniae isolates plus a control strain each were shipped and tested.  
Beginning in 2005, the MIC data was analyzed in two ways.  The first comparison is based on MIC data 
provided by the distributing laboratory and is the method used historically in the QC program.  The new 
methodology provides an analysis of MIC data for all the participating laboratories by using the modal MIC for 
each antibiotic-organism combination as the value to which the other data are compared.  The modal MIC is the 
MIC most frequently reported.  When two MIC values were reported with equal frequency, both were accepted 
as a modal value.  Antibiotic-organism combinations for which there was no consensus on a modal MIC were 
excluded from the analysis.  The rationale for initiating the second analysis recognizes that there is an allowable 
variation of one log2 dilution inherent for any MIC testing system.  This means that there is no one absolutely 
correct MIC value to which all others can be compared.  The modal MIC may be a better representation of this 
‘true’ value than any one laboratory can provide.  For Panel 2010-A, overall serotyping correlation was 100%.  
The modal MIC comparison resulted in an overall correlation of 95.7% with individual participant correlation 
ranging from 82%-100%.  Overall category agreement was 97.8% with individual participant agreement 
ranging from 96.3%-100%.  For Panel 2010-B, six of seven isolates were reported correctly by all labs; one 
isolate was not typeable by three labs.  The modal MIC correlation ranged from 75%-100%.   
 
Conclusions 
 
Streptococcus pneumoniae remains a major cause of invasive bacterial disease in circumpolar regions.  Disease 
rates are highest in indigenous populations.  The impact of pneumococcal conjugate vaccines is clear in the U.S. 
Arctic and is beginning to be seen in N. Canada.  Surveillance for evidence of impact in other circumpolar 
countries will be important to confirm effectiveness and provide support for continuing immunization programs. 
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Haemophilus influenzae 
 
Case Demographics 
 
Greenland, N. Canada, N. Sweden (Norbotten), Norway and the U.S. Arctic reported the occurrence of invasive 
H. influenzae disease during 2010.  Greenland reported no cases.  A total of 137 cases of invasive disease 
caused by H. influenzae were reported to ICS during 2010 by N. Canada, N. Sweden (Norbotten), Norway and 
the U.S. Arctic.  The highest rate of disease among regions reporting cases was in N. Canada (11.2 per 100,000) 
and the lowest in N. Sweden (0.8/100,000).  Median age of cases was highest in Norway (67.4 years) and 
lowest in N. Canada (0.9 year).   
 
Haemophilus influenzae Case Demographics, ICS 2010 Data 
Country Population 
# 
Cases Rate* 
Sex  
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR†) 
Greenland 56,452 0 0 No cases No cases No cases 
N. Canada 151,578 17 11.2 11 (65%) 0.9 (0.1-59) 1 (9%)‡ 
N. Sweden 248,635 2 0.8 1 (50%) 40 (7-73) ‡ 
Norway 4,858,199 89 1.8 34 (38%) 67.4 (0-97.6) 13 (24%)‡  
U.S. Arctic 710,231 29 4.1 17 (59%) 48.3 (0.3-89.7) 4 (14%)‡ 
Total 6,025,095 137 2.3 63 (46%) 57.4 (0-97.6) 18 (19%) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡ Case outcome unknown in (6) N. Canada, (35) Norway cases; N. Sweden did not report case outcomes 
 
When stratified by age, the highest rates of disease for N. Canada and the U.S. Arctic were in the <2 years age 
category, in N. Sweden the highest rate was in the 2-19 years age category, and in Norway the highest rate of 
disease was in the 65+ years age category.   
 
Haemophilus influenzae by Age Category, ICS 2010 Data 
Age  N. Canada N. Sweden Norway U.S. Arctic 
<2 yrs 
Population 5,651 4,463 123,626 21,834 
Cases (%)* 10 (59) 0 (0) 4 (4.5) 10 (34) 
Rate† 177 0 3.2 45.8 
2-19 yrs 
Population 44,672 48,763 1,116,131 186,006 
Cases (%)* 3 (18) 1 (50) 4 (4.5) 2 (7) 
Rate† 6.7 2.1 0.4 1.1 
20-64 yrs 
Population 92,854 142,546 2,895,769 447,453 
Cases (%)* 4 (23) 0 (0) 34 (38) 9 (31) 
Rate† 4.3 0 1.2 2 
65+ yrs 
Population 8,401 52,863 722,673 54,938 
Cases (%)* 0 (0) 1 (50) 47 (53) 8 (28) 
Rate† 0 1.9 6.5 14.6 
All ages  
Population 151,578 248,635 4,858,199 710,231 
Cases 17 2 89 29 
Rate† 11.2 0.8 1.8 4.1 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
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Race 
 
Rates of disease were highest in N. Canada Aboriginal (156.5 per 100,000) and U.S. Arctic (161.5 per 100,000) 
cases less than two years of age.  In the U.S. Arctic, rates of disease were higher in Native populations than in 
non-Native populations in all age categories. 
 
Haemophilus influenzae by Race and Age Categories, ICS 2010 Data 
Age 
(yrs) 
 N. Canada U.S. Arctic 
Aboriginal Non-Aboriginal Native Non-Native 
<2‡ Population 3,834 1,817 6,191 15,643 Cases (rate†) 6 (156.5) 0 (0) 10 (161.5) 0 (0) 
2-19 Population 34,594 10,079 49,754 136,252 Cases (rate†) 3 (8.7) 0 (0) 1 (2) 1 (0.7) 
20-64‡ Population 44,126 48,728 75,228 372,225 Cases (rate†) 3 (6.8) 0 (0) 3 (4) 6 (1.6) 
65+ Population 3,610 4,791 8,551 46,387 Cases (rate†) 0 (0) 0 (0) 4 (46.8) 4 (8.6) 
All 
Ages 
Population 86,164 65,414 139,724 570,507 
Cases (rate†) 12 (13.9) 0 (0) 18 (12.9) 11 (1.9) 
†Number of cases per 100,000 per year 
‡Race unknown in (4) N. Canada cases < 2 years, (1) N. Canada case 20-64 years 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the infection was recorded as the primary clinical presentation. 
In N. Canada, N. Sweden and Norway, the most common clinical presentation associated with H. influenzae 
was bacteremia (35%, 100% and 54% of reported cases, respectively).  In the U.S. Arctic, the most common 
clinical presentation was pneumonia (45%). 
 
Clinical Presentation of Reported Haemophilus influenzae Cases, ICS 2010 Data 
 N. Canada 
n (%) 
N. Sweden 
n (%) 
Norway 
n (%) 
U.S. Arctic 
n (%) 
Pneumonia* 4 (23.5) 0 (0) 27 (30) 13 (45) 
Bacteremia 6 (35) 2 (100) 48 (54) 5 (17) 
Meningitis 4 (23.5) 0 (0) 6 (7) 4 (14) 
Cellulitis 0 (0) 0 (0) 0 (0) 1 (3) 
Septic arthritis 0 (0) 0 (0) 0 (0) 4 (14) 
Empyema 0 (0) 0 (0) 0 (0) 2 (7) 
Osteomyelitis 1 (6) 0 (0) 0 (0) 0 (0) 
Other/Unknown 2 (12) 0 (0) 8 (9) 0 (0) 
Total 17 2 89 29 
*with bacteremia 
 
 
 
 18 
 
Risk Factors 
 
Thirty-five percent of adult (≥ 18 years) cases of H. influenzae reported in the U.S. Arctic indicated chronic 
lung disease as an associated risk factor; 29% indicated smoking, 24% diabetes or alcohol abuse and 12% 
immune suppressive treatment as an associated risk factor.  Twenty-five percent of adult N. Canadian H. 
influenzae cases reported smoking as a risk factor.  N. Sweden and Norway did not report risk factor data. 
 
Vaccination Status 
 
The H. influenzae type b (Hib) conjugate vaccine is required as part of routine childhood vaccination in N. 
Canada, N. Sweden, Norway and the U.S. Arctic.  Two cases of Hib were reported in the U.S. Arctic in children 
less than five years.  One case had received Hib vaccine and one had not.  Data on vaccine status were not 
provided by N. Sweden and Norway. 
 
Haemophilus influenzae Case Vaccination Status for Hib Vaccine, ICS 2010 Data 
 N. Canada U.S. Arctic 
Total cases* eligible for Hib vaccine† 13 12 
Vaccine status known in cases* eligible for Hib vaccine 8 12 
Cases* eligible for Hib vaccine vaccinated (%)‡ 7 (88%) 11 (92%) 
*All serotypes 
†Children less than 5 years of age 
‡Percent of vaccine status known cases 
 
Serotypes 
 
Haemophilus influenzae Serotypes by Country, ICS 2010 Data 
Serotype N. Canada 
n (%) 
Norway 
n (%) 
U.S. Arctic 
n (%) 
a 13 (76) 3 (3) 9 (33) 
b 0 (0) 2 (2) 3 (11) 
c 0 (0) 0 (0) 0 (0) 
d 0 (0) 0 (0) 0 (0) 
e 0 (0) 2 (2) 0 (0) 
f 1 (6) 13 (15) 3 (11) 
Non-typeable 3 (18) 69 (78) 12 (44) 
Total 17 89 27 
 
The most common H. influenzae serotype in N. Canada was type a (76% of cases), in Norway, type f (15% of 
cases) and in the U.S. Arctic it was serotype a (33% of cases each). Non-typeable cases also made up a large 
proportion of cases in Norway (78%) and the U.S. Arctic (44%).  N. Sweden did not provide serotype data.  
 
Outcome 
 
Eighteen deaths were associated with H. influenzae cases reported to ICS in 2010; one from N. Canada, four 
from the U.S. Arctic and 13 from Norway.  N. Sweden did not provide outcome data.   
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Haemophilus influenzae Deaths by Country, ICS 2010 Data 
 N. Canada Norway U.S. Arctic 
No. Deaths 1 13 4 
Case Fatality Ratio 9%* 24%* 14% 
Min-max (yrs) 59 (1 case) 0-94.2 0.7-89.7 
Serotypes (n) a (1) a (1), e (2), f (2), NT (8) a (1), NT (2), unknown (1) 
Clinical 
Presentations (n) Bacteremia (1) 
Bacteremia (9),  
pneumonia (3), other (1) 
Bacteremia (3), pneumonia 
(1) 
*Case outcome unknown in (6) N. Canada, (35) Norway cases 
 
Quality Control 
 
Two QC panels of five H. influenzae and N. meningitidis isolates were shipped and serogrouped or serotyped.  
The single discrepant result was due to the primer set available that did not include all possible serogroups [2]. 
 
Conclusions 
 
Widespread use of Hib conjugate vaccines has led to the virtual disappearance of Hib disease in these 
populations.  Substantial replacement with other serotypes has not occurred.  The proportion of disease caused 
by non-typeable organisms continues to be substantial.   
 20 
Neisseria meningitidis 
 
Case Demographics 
 
Greenland, N. Canada, N. Sweden (Norbotten), Norway and the U.S. Arctic reported the occurrence of N. 
meningitidis during 2010.  A total of 42 cases of invasive disease caused by N. meningitidis were reported to 
ICS.  Norway had the highest disease rate (0.8 per 100,000).  Two deaths associated with N. meningitidis were 
reported from Norway. 
 
Neisseria meningitidis Case Demographics, ICS 2010 Data 
Country Population 
# 
Cases Rate* 
Sex  
M (%) 
Median Age  
(min-max) yrs 
Deaths 
n (CFR†) 
Greenland 56,452 0 0 No cases No cases No cases 
N. Canada 151,578 1 0.7  1 (100) 56.1 (1 case) 0 (0) 
N. Sweden 248,635 1 0.4 0 (0) 79 (1 case) ‡ 
Norway 4,858,199 39 0.8 19 (49) 19 (0.5-81) 2 (6) ‡ 
U.S. Arctic 710,231 1 0.1 0 (0) 1.8 (1 case) 0 (0) 
Total 6,025,095 42 0.7 20 (48) 19 (0.5-81) 2 (6) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Outcome unknown in 7 Norway cases; N. Sweden did not report outcomes 
 
The following table shows cases and rates stratified by age category.   
 
  Neisseria meningitidis by Age Category, ICS 2010 Data 
Age  N. Canada N. Sweden Norway U.S. Arctic 
<2 
yrs 
Population 5,651 4,463 123,626 21,834 
Cases (%)* 0 (0) 0 (0) 4 (10) 1 (100) 
Rate† 0 0 3.2 4.6 
2-19 
yrs 
Population 44,672 48,763 1,116,131 186,006 
Cases (%)* 0 (0) 0 (0) 22 (56) 0 (0) 
Rate† 0 0 2 0 
20-64 
yrs 
Population 92,854 142,546 2,895,769 447,453 
Cases (%)* 1 (100) 0 (0) 9 (23) 0 (0) 
Rate† 1.1 0 0.3 0 
65+ 
yrs 
Population 8,401 52,863 722,673 54,938 
Cases (%)* 0 (0) 1 (100) 4 (10) 0 (0) 
Rate† 0 1.9 0.6 0 
All 
ages 
Population 151,578 248,635 4,858,199 710,231 
Cases 1 1 39 1 
Rate† 0.7 0.4 0.8 0.1 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
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Race 
 
In the U.S. Arctic, the single case of N. meningitidis occurred in a non-AK Native person (rate 0.2/100,000.  In 
N. Canada, the single Nm case occurred in an Aboriginal person (rate 1.2/100,000).  
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the meningococcal infection was recorded as the primary 
clinical presentation. The most common clinical presentation in N. Sweden and Norway for N. meningitidis 
cases was meningitis in 100% and 62% of cases, respectively.  In N. Canada, the one case presented with 
pneumonia and in the U.S. Arctic, septic arthritis was reported as the clinical presentation for the single case. 
 
Clinical Presentation of Reported Neisseria meningitidis Cases, ICS 2010 Data 
 N. Canada 
n (%) 
N. Sweden 
n (%) 
Norway 
n (%) 
U.S. Arctic 
n (%) 
Pneumonia* 1 (100) 0 (0) 1 (2.5) 0 (0) 
Bacteremia 0 (0) 1 (100) 13 (33) 0 (0) 
Meningitis 0 (0) 0 (0) 24 (62) 0 (0) 
Septic arthritis 0 (0) 0 (0) 0 (0) 1 (100) 
Other 0 (0) 0 (0) 1 (2.5) 0 (0) 
Total 1 1 39 1 
*with bacteremia 
 
Serogroups  
 
Forty of 42 cases of invasive N. meningitidis reported to ICS in 2010 included serogroup data.  The table below 
lists serogroups by country.  N. Sweden did not report serogroup data.   
 
Neisseria meningitidis Serogroups by Country, ICS 2010 Data 
Serogroup N. Canada 
n (%) 
Norway 
n (%) 
U.S. Arctic 
n (%) 
B 0 (0) 13 (33) 0 (0) 
C 1 (100) 10 (26) 0 (0) 
W135 0 (0) 2 (5) 1 (100%) 
Y 0 (0) 13 (33) 0 (0) 
Unknown 0 (0) 1 (3) 0 (0) 
Total 1 39 1 
 
Conclusions 
 
Neisseria meningitidis is a relatively uncommon cause of invasive bacterial disease in the circumpolar area 
under surveillance, however, continued surveillance is warranted due to high morbidity and mortality associated 
with outbreaks.
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Group A Streptococcus 
 
Case Demographics 
 
Greenland, N. Canada, N. Sweden and the U.S. Arctic each reported the occurrence of GAS during 2010.  A 
total of 63 cases of invasive disease caused by GAS were reported to ICS; no cases occurred in Greenland in 
2010.  Among regions reporting cases, the rate of disease was highest in N. Canada (7.9 per 100,000) compared 
to the lowest in N. Sweden (3.6 per 100,000).  Seven deaths were associated with GAS, all occurred in the U.S. 
Arctic. 
 
Group A Streptococcus Case Demographics, ICS 2010 Data 
Country Population # Cases Rate* 
Sex 
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR†) 
Greenland 56,452 0 0 No cases No cases No cases 
N. Canada 151,578 12 7.9 8 (67) 49.4 (0.9-78.6) 0 (0)a 
N. Sweden 248,635 9 3.6 1 (11) 76 (52-91) ‡ 
U.S. Arctic 710,231 42 5.9 20 (48) 54.6 (0.9-85) 7 (16.7) 
Total 1,166,896 63 5.4 29 (46) 57.3 (0.9-91) 7 (13.2) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Outcomes not reported from N. Sweden 
a Outcome unknown in 1 case from N. Canada 
 
When stratified by age, the highest rates of disease occurred in children <2 years and in individuals 65+ years of 
age in N. Canada (17.7 per 100,000 and 47.6 per 100,000, respectively).   
 
Group A Streptococcus by Age Category, ICS 2010 Data 
Age  N. Canada N. Sweden U.S. Arctic 
<2 yrs 
Population 5,651 4,463 21,834 
Cases (%)* 1 0 2 
Rate† 17.7 0 9.2 
2-19 yrs 
Population 44,672 48,763 186,006 
Cases (%)* 0 0 5 
Rate† 0 0 2.7 
20-64 yrs 
Population 92,854 142,546 447,453 
Cases (%)* 7 4 26 
Rate† 7.5 2.8 5.8 
65+ yrs 
Population 8,401 52,863 54,938 
Cases (%)* 4 5 9 
Rate† 47.6 9.5 16.4 
All ages  
Population 151,578 248,635 710,231 
Cases 12 9 42 
Rate† 7.9 3.6 5.9 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
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Race 
 
Race and ethnicity data were collected by N. Canada and the U.S. Arctic.  The highest rates of disease occurred 
in N. Canada Aboriginal and U.S. Arctic Native people 65 years and older. 
 
Group A Streptococcus by Race and Age Categories, ICS 2010 Data 
Age 
(yrs) 
 N. Canada U.S. Arctic 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,834 1,817 6,191 15,643 Cases (rate†) 1 (26.1) 0 (0) 2 (32.3) 0 (0) 
2-19 Population 34,594 10,078 49,754 136,252 Cases (rate†) 0 (0) 0 (0) 3 (6) 2 (1.5) 
20-64 Population 44,126 48,728 75,228 372,225 Cases (rate†) 6 (13.6) 1 (2.1) 4 (5.3) 22 (5.9) 
65+ Population 3,610 4,791 8,551 46,387 Cases (rate†) 3 (83.1) 1 (20.9) 3 (35.1) 6 (12.9) 
All 
Ages 
Population 86,164 65,414 139,724 570,507 
Cases (rate†) 10 (11.6) 2 (3.1) 12 (8.6) 30 (5.3) 
†Number of cases per 100,000 per year 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the infection was recorded as the primary clinical presentation. 
The most common clinical presentation for GAS cases in N. Sweden and N. Canada (100%) was bacteremia, 
100% and 33%, respectively. In the U.S. Arctic the most common clinical presentation was cellulitis (40%).     
 
Clinical Presentation of Reported group A Streptococcus Cases, ICS 2010 Data 
 N. Canada 
n (%) 
N. Sweden 
n (%) 
U.S. Arctic 
n (%) 
Bacteremia 4 (33) 9 (100) 6 (14) 
Pneumonia* 1 (8) 0 (0) 6 (14) 
Empyema 1 (8) 0 (0) 1 (2) 
Cellulitis* 2 (17) 0 (0) 17 (40) 
Necrotizing fasciitis 1 (8) 0 (0) 2 (5) 
Septic arthritis 2 (17) 0 (0) 2 (5) 
Meningitis 0 (0) 0 (0) 2 (5) 
Strep toxic shock 1 (8) 0 (0) 3 (7) 
Endocarditis 0 (0) 0 (0) 2 (5) 
Bursitis 0 (0) 0 (0) 1 (2) 
Total 12 9 42 
*with bacteremia 
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Risk Factors 
 
Chronic lung disease was the most common risk factor associated with adult (≥18 years) GAS cases in the U.S. 
Arctic; it was reported in 35% of cases.  In N. Canada, the most common risk factor reported was diabetes 
which occurred in 36% of the adult cases.  N. Sweden did not report risk factor data. 
 
Group A Streptococcus Risk Factor/Medical Conditions in Adults*, ICS 2010 Data† 
 N. Canada 
n (%) 
U.S. Arctic 
n (%) 
Cigarette Smoking 2 (18) 6 (16) 
Alcohol Abuse 3 (27) 4 (11) 
Chronic Lung Disease and/or Asthma 1 (9) 13 (35) 
Immunosuppressive Therapy 0 (0) 3 (8) 
Diabetes 4 (36) 8 (22) 
Injection Drug Use 0 (0) 2 (5) 
Asplenia 0 (0) 0 (0) 
Total Adult* Cases 11 37 
*≥ 18 years 
†Multiple risk factors may be reported per case 
 
Outcome 
 
Seven deaths in cases with GAS were reported from the U.S. Arctic (CFR 16.7%); five occurred in the 20-64 
years old age category and two in persons ≥ 65.  No deaths were reported in N. Canada.  N. Sweden did not 
report case outcome data. 
 
Conclusions 
 
These data suggest higher rates in indigenous populations, particularly in young children and older adults.  
Increased awareness of risk may help target improved treatment responses. 
 
 25 
Group B Streptococcus 
 
Case Demographics 
 
Greenland, N. Canada, N. Sweden and the U.S. Arctic each reported the occurrence of GBS during 2010.  A 
total of 68 cases of invasive disease caused by GBS were reported to ICS.  Greenland reported no cases.  
Among regions reporting cases, the rate of disease was highest in the U.S. Arctic (7.5 per 100,000) compared to 
N. Canada (2 per 100,000).  Four deaths were associated with GBS in 2010. 
 
Group B Streptococcus Case Demographics, ICS 2010 Data 
Country Population 
# 
Cases Rate* 
Sex 
M (%) 
Median Age 
(min-max) yrs 
Deaths 
n (CFR†) 
Greenland 56,452 0 0 No cases No cases No cases 
N. Canada 151,578 3 2 1 (33) 55.2 (0-89) 0 (0) 
N. Sweden 248,635 12 4.8 4 (33) 63 (0-93) ‡ 
U.S. Arctic 710,231 53 7.5 27 (51) 55.5 (0-94.2) 4 (7.6) 
Total 1,166,896 68 5.8 32 (47) 56.4 (0-94.2) 4 (7.1) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Outcomes not reported from N. Sweden 
 
When stratified by age, the highest rates of disease occurred in cases less than two years of age in all regions.   
 
Group B Streptococcus by Age Category, ICS 2010 Data 
Age  N. Canada N. Sweden U.S. Arctic 
<2 yrs 
Population 5,651 4,463 21,834 
Cases (%)* 1 (33) 2 (17) 14 (26) 
Rate† 17.7 44.8 64.1 
2-19 yrs 
Population 44,672 48,763 186,006 
Cases (%)* 0 (0) 0 (0) 0 (0) 
Rate† 0 0 0 
20-64 yrs 
Population 92,854 142,546 447,453 
Cases (%)* 1 (33) 5 (42) 23 (43) 
Rate† 1.1 3.5 5.1 
65+ yrs 
Population 8,401 52,863 54,938 
Cases (%)* 1 (33) 5 (42) 16 (30) 
Rate† 11.9 9.5 29.1 
All ages  
Population 151,578 248,635 710,231 
Cases 3 12 53 
Rate† 2 4.8 7.5 
*Proportion of total cases in each country/region 
†Number of cases per 100,000 per year 
 
There were six cases of early-onset disease (cases less than 7 days old) in the U.S. Arctic (0.6 cases per 1,000 
births) one case in N. Canada (0.4 cases per 1,000 births) and one case in N. Sweden (0.4 cases per 1,000 
births). 
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Race 
 
Race and ethnicity data were collected in N. Canada and the U.S. Arctic.  The overall rates of disease caused by 
GBS were similar in AK Native and Aboriginal people compared to non-Native and non-Aboriginal people.  
The highest rates of disease occurred in Aboriginal and AK Native children less than 2 years old, although the 
non-Native rate in children less than 2 years was almost the same as the AK Native rate in the same age 
category. 
 
Group B Streptococcus by Race and Age Categories, ICS 2010 Data 
Age 
(yrs) 
 N. Canada U.S. Arctic 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,834 1,817 6,191 15,643 Cases (rate*) 1 (26.1) 0 (0) 4 (64.6) 10 (63.9) 
2-19 Population 34,594 10,078 49,754 136,252 Cases (rate*) 0 (0) 0 (0) 0 (0) 0 (0) 
20-64 Population 44,126 48,728 75,228 372,225 Cases (rate*) 1 (2.3) 0 (0) 6 (8) 17 (4.6) 
65+ Population 3,610 4,791 8,551 46,387 Cases (rate*) 0 (0) 1 (20.9) 1 (11.7) 15 (32.3) 
All 
Ages 
Population 86,164 65,414 139,724 570,507 
Cases (rate*) 2 (2.3) 1 (1.5) 11 (7.9) 42 (7.4) 
*Number of cases per 100,000 per year 
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each patient’s 
individual medical record associated with the invasive bacterial illness.  In cases with multiple discharge 
diagnoses, the most serious diagnosis related to the infection was recorded as the primary clinical presentation. 
In the U.S. Arctic, bacteremia (53%) was the most common clinical presentation reported for cases of GBS in 
2010 followed by cellulitis (13%) and septic arthritis (9%).  Two cases in N. Canada presented with pneumonia, 
the third with bacteremia.  Ten of twelve cases in N. Sweden were reported as bacteremia which may reflect a 
difference in reporting practices; two cases presented with meningitis. 
 
Clinical Presentation of Reported group B Streptococcus Cases, ICS 2010 Data 
 N. Canada 
n (%) 
N. Sweden 
n (%) 
U.S. Arctic 
n (%) 
Bacteremia 1 (33) 10 (83) 28 (53) 
Pneumonia* 2 (67) 0 (0) 4 (8) 
Meningitis 0 (0) 2 (17) 3 (6) 
Septic arthritis 0 (0) 0 (0) 5 (9) 
Cellulitis* 0 (0) 0 (0) 7 (13) 
Osteomyelitis 0 (0) 0 (0) 1 (2) 
Endocarditis 0 (0) 0 (0) 3 (6) 
Peritonitis 0 (0) 0 (0) 2 (4) 
Total 3 12 53 
*with bacteremia 
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Risk Factors 
 
Thirty-six percent of GBS adult (≥ 18 years) cases reviewed in the U.S. Arctic indicated diabetes as a risk factor 
in 2010; 23% were smokers, 15% had chronic lung disease, 8% were receiving immune suppressive treatment 
and 5% abused alcohol.  In N. Canada, 50% of adult cases reported chronic lung disease and/or alcohol abuse.  
N. Sweden does not report risk factor data. 
 
Outcome 
 
Four deaths in cases with GBS were reported in the U.S. Arctic (CFR 7.6%); one death occurred in the less than 
2 years age category, one death occurred in the 20-65 years age category and two deaths occurred in the 65+ 
age category.  N. Sweden did not report case outcome data. 
 
Conclusions 
 
Guidelines for universal screening of pregnant women for GBS carriage were established in 2002 which have 
resulted in decreases in early onset disease.  Cases continue to occur in older age groups which warrants 
continued surveillance.
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CONCLUSIONS 
 
The ICS program continued to expand in 2010.  Monitoring rates of disease and levels of antimicrobial 
resistance in S. pneumoniae, H. influenzae, N. meningitidis, GAS and GBS via use of the ICS system is 
important in providing data on groups at risk for disease, measurement of effectiveness of prevention 
measures, and emerging challenges in serotype distribution and antimicrobial resistance.  Efforts to 
expand ICS to include all circumpolar nations will continue. 
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PARTICIPANTS 
 
International Circumpolar Surveillance (ICS) Participants, 2009 
 
FINLAND 
Reference 
Laboratory 
National Public Health Institute (KTL) Laboratory, Oulu 
Laboratories Et.-Pohjanmaan sh-piiri, Seinäjoen sairaalan mikrobiol. lab. 
Etelä-Karjalan keskussairaalan kl.mikrobiologian laboratorio 
HY – Serobakteriologian laitos 
Jorvin sairaala, kliinisen mikrobiologian laboratorio 
KYS – Mikrobiologian laboratorio 
Kainuun keskussairaalan mikrobiologian laboratorio 
Kanta-Hämeen keskussairaalan mikrobiologian laboratorio 
Keski-Pohjanmaan keskussairaalan mikrobiologian laboratorio 
Keski-Suomen keskussairaalan mikrobiologian laboratorio 
Kymenlaakson keskussairaalan mikrobiologian laboratorio 
Lapin keskussairaalan mikrobiologian laboratorio 
Länsi-Pohjan keskussairaalan laboratorio 
Mikkelin keskussairaalan mikrobiologian laboratorio 
OYKS – Mikrobiologian laboratorio 
Oulun kiakonissalairoksen laboratorio 
Pohjois-Karjalan keskussairaalan mikrobiologian laboratorio 
Päijät-Hämeen keskussairaalan mikrobiologian laboratorio 
Rauman aluesairaalan laboratorio 
Satakunnan keskussairaalan mikrobiologian laboratorio 
Savonlinnan keskussairaalan laboratorio 
TAYS – Mikrobiologian laboratorio 
TYKS – Mikrobiologian laboratorio 
Vaasan keskussairaalan mikrobiologian laboratorio 
 
GREENLAND 
Reference 
Laboratories 
Statens Serum Institute, Copenhagen, Denmark 
Centralab at Queen Ingrid’s Hospital, Nuuk, Greenland 
Laboratories Nanortalik Hospital 
Qaqortoq Hospital 
Narsaq Hospital 
Paamiut Hospital 
Maniitsoq Hospital 
Sisimut Hospital 
Aasiaat Hospital 
Qasigiannguit Hospital 
Ilulissat Hospital 
Qeqertarsuaq Hospital 
Uummannaq Hospital 
Upernavik Hospital 
Qaanaaq Hospital 
Ammassalik Hospital 
Ittoqqortoormiit Hospital 
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ICELAND 
Reference 
Laboratory 
Department of Microbiology, Landspitali University Hospital, 
Reykjavik 
Laboratories Akranes Hospital 
Isafjordur District Hospital 
Stykkisholmur Local Health Center 
St. Joseph’s Hospital Hafnarfjorour 
Municipal Hospital of Vestmannaeyjar 
Akureyri 
Egilstadir Health Center 
Selfoss Health Center 
Sudurnes Health Center (Keflavik) 
Regional Hospital Neskaupstadur 
 
NORTHERN CANADA 
Laboratory Centre 
for Disease Control 
Respiratory Division, Bureau of Infectious Diseases, Laboratory 
Centre for Disease Control, Ottawa 
Reference 
Laboratories 
National Centre for Streptococcus, Provincial Laboratory of Public 
Health, Edmonton, AB 
Laboratoire de Santé Publique du Québec, Montréal, QC 
National Centre for Meningococcus, Provincial Laboratory of Public 
Health, Winnipeg, MB 
Laboratories Whitehorse General Hospital, Whitehorse, YK 
Stanton Regional Health Board, Yellowknife, NT 
H.H. Williams Memorial Hospital, Hay River, NT 
Inuvik Regional Hospital, Inuvik, NT 
Baffin Regional Hospital, Iqaluit, NU 
Churchill Regional Health Authority, Churchill, MB 
Cadham Provincial Laboratory, Winnipeg, MB 
Ungava Tulattavik Health Centre, Kuujjuaq, QC 
Inulitsavik Hospital, Puvirnituq, QC 
Cree Health Board, Chisasibi, QC 
CSSSR, Chibougamou, QC 
Val d’Or Hospital, Val d’Or, QC 
Melville Hospital, Goose Bay, NL 
Newfoundland Public Health Laboratory, St. John’s, NL 
Public Health Yukon Communicable Disease Control, Whitehorse, YK 
Health Protection Unit, Government of NWT, Yellowknife, NT 
JA Hildes Northern Medical Unit, Winnipeg, MB 
Régie Régionale de la Santé et des Services Sociaux, Kuujjuaq, QC 
Région Cri de la Baie James, Module de Santé Publique, Montreal, 
QC 
Communicable Disease Control, Health Laborador Corporation, 
Goose Bay, NL 
IMPAct Coordinator, Vaccine Evaluation Centre, Vancouver, BC 
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NORTHERN SWEDEN 
Reference 
Laboratory 
Department of Bacteriology, Swedish Institute for Infectious Disease 
Control, Stockholm 
Laboratories Department of Microbiology, Sunderby Hospital, Lulea 
 
NORWAY 
Reference 
Laboratory 
Oslo/Tromsö 
Laboratories Frederikstad, Østf. SSH 
Sarpsborg SH 
Akershus SSH, SiA 
Bœrum SH 
Aker SH 
Fürsts laborat, Oslo 
Dr. Willes med.lab. 
Radiumhospitalet 
Folkehelsa, vir.lab. 
Folkehelsa, bakt.lab. 
Forsv.mik.lab.Folk.h. 
Rikshospitalet, mik.lab. 
Ullevål SH, mik.lab. 
Lab. klin. mikrob. Oslo 
Lillehammer mik.lab 
Elverum mik.lab. 
Buskerud SSH, mik.lab. 
Vestfold SSH, mik.lab. 
Telelab 
Vest-Agder SSH, mik.lab. 
Rogaland SSH, mik.lab. 
Haukeland SH, mik.lab. 
Sogn-Fk. SSH, mik.lab. 
Ålesund FSH, mik.lab. 
Molde FSH, mik.lab. 
Trondheim RSH, mik.lab. 
Innherred SH, mik.lab. 
Namdal SH, mik.lab. 
Nordland SSH, mik.lab. 
Tromsø RSH, mik.lab. 
Kirkenes SH, mik.lab. 
Laboratorium INA/div. 
Haugesund, mik.lab. 
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U.S. ARCTIC 
Reference 
Laboratory 
Arctic Investigations Program, National Center for Infectious 
Diseases, Centers for Disease Control and Prevention, Anchorage, AK 
Laboratories Alaska Native Medical Center, Anchorage, AK 
Alaska Regional Hospital, Anchorage, AK 
Bartlett Regional Hospital, Juneau, AK 
Bassett Army Hospital, Fort Wainwright, AK 
Central Peninsula General Hospital, Soldotna, AK 
Cordova Community Medical Center, Cordova, AK 
Elmendorf Air Force Base Hospital, Anchorage, AK 
Fairbanks Memorial Hospital, Fairbanks, AK 
Kanakanak Hospital, Dillingham, AK 
Ketchikan Regional Hospital, Ketchikan, AK 
Manilaq Medical Center, Kotzebue, AK 
Norton Sound Regional Hospital, Nome, AK 
Petersburg Medical Center, Petersburg, AK 
Providence Alaska Medical Center, Anchorage, AK 
Providence Island Medical Center, Kodiak, AK 
Samuel Simmonds Memorial Hospital, Barrow, AK 
Sitka Community Hospital, Sitka, AK 
South Peninsula Hospital, Homer, AK 
Southeast Area Regional Health Corporation, Sitka, AK 
State Public Health Laboratory, Division of Public Health, 
Department of Health and Social Services, Anchorage, AK 
Valdez Community Hospital, Valdez, AK 
Valley Hospital, Palmer, AK 
Wrangell General Hospital, Wrangell, AK 
Yukon-Kuskokwim Delta Regional Hospital, Bethel, AK 
 
